Publication | Closed Access

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

Oral Trastuzumab EmtansineOncologyBreast OncologyPrimary ResultsMedicinePathologyBreast CancerCancer TreatmentPharmacologyRadiation OncologyTumor Biology